Study of a new treatment for advanced cancers with a specific gene change
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must have a specific change (the TP53 R175H mutation) and you must have a certain immune marker (HLA-A*02:01) in your blood.
- Your cancer should be advanced (cannot be removed by surgery) and you should have tried at least one standard treatment already.
- You must be able to care for yourself (up and about more than half of the day).
- You cannot have certain other serious medical conditions (like recent heart problems, organ transplant, or another cancer in the last few years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
This trial tests a new type of immune cell therapy called TCR-T that targets a specific genetic change (KRAS mutation) found in some pancreatic, colorectal, and lung cancers. If you have the right genetic markers and previous treatments haven't worked, this study may offer a new option.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.